Bagher Larijani, Masoud Houshmand, Ghamar Soltan Dorraj, Farzaneh Darvishzadeh,
Volume 4, Issue 3 (17 2005)
Abstract
Background: Mitochondria is one of the intracellular organelle with specific DNA. Some diseases caused by mtDNA mutations have been reported up to now. Mutation of A3243G and deletion of 5kb are two of them that related to Diabetes type II. The aim of this study was to evaluate the frequency of A3243G mutation and 5kb mt DNA deletion in type II diabetic patients.
Methods: The DNA extracted from blood of 130 patients with diabetes type II. Serum insulin of the patients were also measured. Sequence assigning, PCR – RFLP and SSCP methods were used to detect the A3243G or other mutation in mitochondrial tRNA (leu) gene. Standard and multiplex PCR were used to detect 5kb deletion in patient’s mt DNA and were compared with 40 healthy persons.
Results :We couldn’t identify any deletion of 5kb or A3243G point mutation in our patients but SSCP results showed new pattern of PCR Product in patients. An “A” nucleotide deletion in A 3314 position was detected in mitochondrial ND1 gene in 6 patients. So far this point deletion has not been reported.
Conclusion: Identification of the mitochondrial gene mutations helps to preclinical diagnosis of diabetes type 2. More research is necessary in this field.
Ozra Tabatabaei Malazy, Ramin Heshmat, Seyed Akhavan Hejazy Mogaddam Sa, Eghbal Taheri, Seddigheh Soheilykhah, Farzaneh Darvishzadeh, Bagher Larijani,
Volume 5, Issue 1 (18 2005)
Abstract
Background: Metformin is usually using for glycemic control in type 2 diabetes mellitus. The drug is the first line for obese patients without renal or liver failure. Different pharmaceutical types of Metformin are available. As a clinical trial, we compared effects of Aria Metformin (product of Aria pharmaceutical company, Iran) with Merck Metformin or Glucophage (product of Merck pharmaceutical company, France), in diabetic patients.
Methods: This double blind randomized clinical trial study performed with 60 non- pregnant diabetic patients, in order to comparison of therapeutic effects of combination therapy (Glibenclamide + Metformin "Aria or Merck") in a 12 weeks period. We evaluated FBS, BS 2hpp, HbA1c, lipid profile, liver function tests, weight, BMI and common or uncommon side effects.
Results: Not only each of two pharmaceutical types of Metformin had the same therapeutic effects for controlling of glycemia, lipid profile and weight, but also there were not difference between them in side effects. Distention was the most common side effects of two types products (33%). There is not significant difference between them in common side effects. 70% of patients were satisfied with each two kinds of Metformin.
Conclusion: It seems, in view of beneficial therapeutic effects of Aria Metformin, low rate of side effects, and finally low cost, Aria Metformin is a good choice.
